Shanghai Pharma emphasizes its commitment to research and development (R&D) innovation as a core aspect of its operations. The company focuses on advancing pharmaceutical technologies to enhance drug efficacy and safety. This includes the development of new formulations and delivery systems that aim to improve patient outcomes. By investing in R&D, Shanghai Pharma seeks to stay at the forefront of the pharmaceutical industry, ensuring that it can meet the evolving needs of healthcare providers and patients alike.

In addition to R&D, Shanghai Pharma employs lean manufacturing techniques to optimize its production processes. This approach aims to increase efficiency, reduce waste, and ensure high-quality output in its manufacturing facilities. The company also emphasizes robust distribution and retail services, ensuring that its products are effectively delivered to market. By integrating these technologies and services, Shanghai Pharma is positioned to expand its reach and enhance its product offerings in the competitive pharmaceutical landscape.

China

Shanghai Pharmaceuticals Holding Co. Ltd. ("SPH") is a vertically-integrated and diversified pharmaceutical group. The company has dual listings on the stock exchanges in Shanghai (601607) and Hong Kong (02067) respectively. The company provides leading healthcare services in: Research & Development, Manufacturing, Distribution and Retail.  

In 2019, SPH reported revenues of US$26.5bn, making the company one of the country's major forces in the industry. SPH is one of the few listed pharmaceutical companies with a leading position in both manufacturing and distribution in China. It is included in the constituent stocks of the SSE 180, CSI 300 indices and MSCI.

Shanghai Pharma

Company Details